Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$8.01 ▼ -0.52
(-6.10%)
MKT CAP: $85.6M • VOL: 30.0K
52W L $4 52W H $19
ROARABLE / RQD
D+ • 54/100
PIOTROSKI
3 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$7
MEDIAN
$9
MEAN
$9
HIGH
$11
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ATRA TAPE
ATRA // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $9.69 | $9.21 | 2025-02-14 | $7.29 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $10.09 | $9.45 | 2025-02-06 | $7.53 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $9.13 | $8.81 | 2025-01-29 | $7.69 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $8.17 | — | 2025-01-17 | $7.85 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $7.05 | $7.61 | 2025-01-09 | $7.13 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $9.53 | $8.33 | 2024-12-18 | $6.97 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $7.77 | $8.09 | 2024-12-04 | $7.45 | -4.3% | 48% | C |